Duane D. Miller, Ph.D.
Van Vleet Professor and Chair
Department of Pharmaceutical Sciences
The University of Tennessee Health Science Center
227c Johnson Building
847 Monroe Avenue
Memphis, TN 38163
Tel: (901) 448-6026
Fax: (901) 448-6828
Email: Duane D. Miller
- Ph.D. Institution: University of Washington, Medicinal Chemistry Department
The design, synthesis and characterization of new drug molecules for mechanism based structure-activity relationships is the primary focus of our laboratory. One of the important areas of research is studying new drugs affecting the central and peripheral nervous systems. Our laboratory is very interested in the design of drugs that are used to treat asthma, emphysema and obesity. Other areas of keen interest are drugs used to treat and diagnose prostate cancer and diabetic complications.
We are currently investigating the modification of a molecule called trimetoquinol which is used in Japan. We are attempting to make chemical structural changes in the molecule so that it can be used to activate selectively beta 2-adrenergic receptors found in lung tissue. We are also attempting to make changes that will also convert this same molecule into a beta 3-adrenergic receptor agonist for the treatment of obesity. The latter receptors are found in adipose tissue and upon activation lead to the breakdown of fat. We are also in the process of studying medetomidine, an alpha-adrenergic agonist. We are changing the structure of medetomidine chemically to see if such changes can lead to a better understanding of how this molecule binds to the various subtypes of a- adrenergic receptors.
We are very interested in drugs that could interfere with the craving for cocaine. We are now synthesizing drugs that will block specific glutamate receptors found in the brain and hopefully such new information will help us find an agent that will be useful in treating cocaine addiction.
Drugs that bind to androgen receptors and their relationship to prostate cancer are being studied in our laboratory. A major project is directed toward synthesizing new radiolabeled androgen ligands and we plan to use this technology towards imaging metastatic prostate cancer.
A major enzyme in the development of diabetic complications such as cataracts is thought to be the enzyme aldose reductase. Our laboratory has developed irreversible inhibitors for studying this enzyme.
- He H, Williams-Guy K, Pagadala J, Presley CS, Miller DD, Steinle JJ, Yates CR. A sensitive and fast LC-MS/MS method for determination of Î²-receptor agonist JP-49b: Application to a pharmacokinetic study in rats. J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Feb 8;953-954C:86-91. doi: 10.1016/j.jchromb.2014.01.031. [Epub ahead of print] PubMed PMID: 24576769.
- Chen J, Slominski AT, Miller DD, Li W. Effects of sidechain length and composition on the kinetic conversion and product distribution of vitamin D analogs determined by real-time NMR. Dermatoendocrinol. 2013 Jan 1;5(1):142-9. doi: 10.4161/derm.24339. PubMed PMID: 24494047; PubMed Central PMCID: PMC3897582.
- Slominski A, Kim TK, Zmijewski MA, Janjetovic Z, Li W, Chen J, Kusniatsova EI, Semak I, Postlethwaite A, Miller DD, Zjawiony JK, Tuckey RC. Novel vitamin D photoproducts and their precursors in the skin. Dermatoendocrinol. 2013 Jan 1;5(1):7-19. Review. PubMed PMID: 24494038; PubMed Central PMCID: PMC3897599.
- Narayanan R, Yepuru M, Coss CC, Wu Z, Bauler MN, Barrett CM, Mohler ML, Wang Y, Kim J, Snyder LM, He Y, Levy N, Miller DD, Dalton JT. Discovery and preclinical characterization of novel small molecule TRK and ROS1 tyrosine kinase inhibitors for the treatment of cancer and inflammation. PLoS One. 2013 Dec 26;8(12):e83380. doi: 10.1371/journal.pone.0083380. eCollection 2013. PubMed PMID: 24386191; PubMed Central PMCID: PMC3873281.
- Fells JI, Lee SC, Norman DD, Tsukahara R, Kirby JR, Nelson S, Seibel W, Papoian R, Patil R, Miller DD, Parrill AL, Pham TC, Baker DL, Bittman R, Tigyi G. Targeting the hydrophobic pocket of autotaxin with virtual screening of inhibitors identifies a common aromatic sulfonamide structural motif. FEBS J. 2013 Dec 7. doi: 10.1111/febs.12674. [Epub ahead of print] PubMed PMID: 24314137.
- Wang J, Chen J, Miller DD, Li W. Synergistic combination of novel tubulin inhibitor ABI-274 and vemurafenib overcome vemurafenib acquired resistance in BRAFV600E melanoma. Mol Cancer Ther. 2014 Jan;13(1):16-26. doi: 10.1158/1535-7163.MCT-13-0212. Epub 2013 Nov 18. PubMed PMID: 24249714.